The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

Registration is open for free 'Living Your Best Life with Parkinson's Disease' event, hosted by Tallahassee's Sweat Therapy Fitness on March 1 ...

The Parkinson’s Foundation estimates that 15,000 people here in Wisconsin have Parkinson’s disease, and that number is only ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...